Use of Transmucosal Ketamine in Post Stroke Depression
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Studies have shown that ketamine is very effective and has a quick onset in treatment of
depression. Most of these studies used intravenous ketamine in an inpatient setting and there
are no large trials examining its use in Post Stroke Depression (PSD). There have been only
few studies that have used other routes of administration (i.e., oral, transmucosal,
intranasal, intramuscular) of ketamine which provided symptom relief for depression. The
purpose of this study is to assess the effectiveness and safety of use of transmucosal
ketamine in treatment of PSD. We hypothesize that fast acting antidepressant effects can be
achieved with tolerable side effects for translation into the general post-stroke population.
To test our hypothesis, the specific aim is to: (1) demonstrate that transmucosal
administration of ketamine is feasible within the post-stroke depression population and has
tolerable side effects. Exploratory aims will include assessment if ketamine also produces
fast acting antidepressant effects.